By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government ...

Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the first single shot to ...

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

The settlement could go as high as $2.25 billion.

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the ...

Investing.com -- Moderna has agreed to pay up to $2.25 billion to Genevant Sciences, a subsidiary of Roivant Sciences (NASDAQ ...